ALMED Share Price

Open 6.10 Change Price %
High 6.10 1 Day -0.32 -5.24
Low 5.72 1 Week -0.31 -5.08
Close 5.79 1 Month 0.11 1.94
Volume 8062 1 Year 0.38 7.02
52 Week High 6.47
52 Week Low 4.33
ALMED Important Levels
Resistance 2 6.14
Resistance 1 6.00
Pivot 5.87
Support 1 5.58
Support 2 5.44
EPA France Most Active Stocks
AVQ 0.37 15.62%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
VK 5.39 1.32%
GSZ 17.56 3.97%
GSZ 17.56 3.97%
GSZ 17.56 3.97%
EPA France Top Gainers Stocks
ALEUA 7.43 24.66%
CHSR 11.50 20.42%
HDP 1.92 17.79%
APAM 33.78 15.72%
APAM 33.78 15.72%
AVQ 0.37 15.62%
MLLOI 3.80 15.15%
DEXB 17.47 13.89%
DEXB 17.47 13.89%
MT 4.53 12.97%
EPA France Top Losers Stocks
ALADO 0.06 -14.29%
SEC 0.80 -12.09%
SEC 0.80 -12.09%
ALMER 15.01 -11.71%
MLIML 0.24 -11.11%
ALTRA 1.25 -10.71%
AVT 0.09 -10.00%
AVT 0.09 -10.00%
AVT 0.09 -10.00%
AVT 0.09 -10.00%

Medicrea International SA (EPA: ALMED)

ALMED Technical Analysis 3
As on 27th Feb 2017 ALMED Share Price closed @ 5.79 and we RECOMMEND Buy for LONG-TERM with Stoploss of 5.44 & Buy for SHORT-TERM with Stoploss of 5.62 we also expect STOCK to react on Following IMPORTANT LEVELS.
ALMED Target for February
1st Target up-side 6.22
2nd Target up-side 6.55
3rd Target up-side 6.88
1st Target down-side 5.28
2nd Target down-side 4.95
3rd Target down-side 4.62
ALMED Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website
ALMED Address
14 Porte du Grand
Lyon, 01 700
Phone: 33 4 72 01 87 87
Fax: 33 4 72 01 87 88
ALMED Latest News
Spinal rod maker decides to provide lifetime warranties. What?!!   MedCity News   - 26th Oct 16
FDA clears pediatric spine implants from Medicrea   Mass Device   - 22nd Oct 16
Medicrea Announces Closing of €20 million Financing to Support Commercial ...   GlobeNewswire (press release)   - 22nd Aug 16
Medicrea raises over $22M toward spinal rod commercialization   FierceBiotech   - 11th Aug 16
Medicrea raises $22m, taps Globus Medical co-founder Kienzle   OrthoSpineNews   - 10th Aug 16
Medicrea Announces €20 million Financing to Support Commercial Expansion of ...   PR Web (press release)   - 10th Aug 16
Three patients discuss experience with Medicrea's UNiD rods for Scoliosis ...   OrthoSpineNews   - 22nd Jun 16
MEDICREA Appoints New Vice President of US Sales   Business Wire (press release)   - 15th Sep 15
MEDICREA Announces US Launch of New Generation LigaPASS   Business Wire (press release)   - 01st May 15
FDA Clears World's First Patient-Specific Spinal Rod   Business Wire (press release)   - 11th Nov 14
Interactive Technical Analysis Chart Medicrea International SA ( ALMED EPA France )
Java support must be enabled in order to display FnCharts.
You can download Java from
Your Comments and Response on Medicrea International SA
ALMED Business Profile
Medicrea International Société Anonyme designs, develops, manufactures, and distributes surgical implants and instrumentation for spinal surgery primarily in France, the United States, and the United Kingdom. The company offers a range of implants for the cervical spine, including GRANVIA C, a MRI compatible ceramic cervical disc; C-JAWS, an anterior cervical spinal fixation system; IMPIX C, a sterile PEEK Optima cervical inter body device; Impix C+, a sterile PEEK Optima cervical inter body device that is prefilled with bone substitutes; IMPIX C+ on holder, a sterile PEEK Optima cervical inter body device, which is prefilled with bone substitutes, as well as preassembled on disposable holder; IMPIX Manta+ on holder, a sterile PEEK Optima cervical inter body device, which is preassembled on holder and delivered with disposable instrumentation kit; and LaminoJAWS, a cervical laminoplasty implant with a posterior approach. It also provides implants for the thoracic and lumbar spine comprising PASS LP, a polyaxial spine system; PASS ANT, a polyaxial low profile thoraco-lumbar system for anterior approach; X-JAWS, a lateral lumbar spinal fixation system; L-JAWS, an anterior lumbar spinal fixation system; IMPIX TLIF, a sterile PEEK Optima lumbar inter body device for transforaminal approach; IMPIX ALIF, a sterile PEEK Optima lumbar inter body device for anterior approach; IMPIX LR, a sterile PEEK Optima lumbar ramp shaped inter body device for posterior approach; and OSMOSYS, a synthetic biphasic substitute. The company’s implants are designed to treat scoliosis, degenerative deformation, trauma, and tumors; and are used in various traditional and advanced surgical techniques, such as minimally-invasive surgery. Medicrea International Société Anonyme was founded in 1990 and is headquartered in Lyon, France.